A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 72
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : GEC
Long Form : gene expression classifier
No. Year Title Co-occurring Abbreviation
2021 Combined molecular and histologic end points inform cancer risk estimates for thyroid nodules classified as atypia of undetermined significance. AUS, AUS-C, NIFTP
2021 Comparison of Afirma GEC and GSC to Nodules Without Molecular Testing in Cytologically Indeterminate Thyroid Nodules. BCR, GSC, PPV
2021 Molecular Testing Has Limited Utility in the Surgical Evaluation of Bethesda III Thyroid Nodules. AUS/FLUS, FNA, ROM, ThyroSeq
2021 Performance of Afirma Gene Sequencing Classifier versus Gene Expression Classifier in thyroid nodules with indeterminate cytology. BCR, FNA, GSC, NPV, PPV
2021 Performance of Afirma genomic sequencing classifier vs gene expression classifier in Bethesda category III thyroid nodules: An institutional experience. AUS/FLUS, BCR, GSC, NPV, PPV, RHM, RSS
2021 Repeat Fine Needle Aspiration Cytology Refines the Selection of Thyroid Nodules for Afirma Gene Expression Classifier Testing. FNA, MT, NIFTP
2021 Single Institution Experience with Afirma and Thyroseq Testing in Indeterminate Thyroid Nodules. GSC, PPV
2021 Thyroseq v3, Afirma GSC, and microRNA Panels Versus Previous Molecular Tests in the Preoperative Diagnosis of Indeterminate Thyroid Nodules: A Systematic Review and Meta-Analysis. AUC, GSC, ITNs, NIFTP, NLR
2020 American Thyroid Association Sonographic Risk and Afirma Gene Expression Classifier Alone and in Combination for the Diagnosis of Thyroid Nodules with Bethesda Category III Cytology. ATA-US, HS, IS, LS, NPV, PPV, VLS
10  2020 Comparison of Afirma Gene Expression Classifier with Gene Sequencing Classifier in indeterminate thyroid nodules: A single-institutional experience. GSC, NIFTP
11  2020 Diagnostic performances of the Afirma Gene Sequencing Classifier in comparison with the Gene Expression Classifier: A meta-analysis. BCRs, GSC, NPV, PPV, ROMs, RRs
12  2020 Diagnostic Value of Molecular Testing in Sonographically Suspicious Thyroid Nodules. ATA, PPV
13  2020 Long-Term Outcomes of Thyroid Nodule AFIRMA GEC Testing and Literature Review: An Institutional Experience. ---
14  2020 Quality of Life Following Molecular Marker Testing for Indeterminate Thyroid Nodules. FNA, QoL
15  2020 Urine cytology suspicious for urothelial carcinoma: Prospective follow-up of cases using cytology and urine biomarker-based ancillary techniques. AUCs, FGFR3, FISH, HG, TERT, UC
16  2020 UTILITY OF AFIRMA GENE EXPRESSION CLASSIFIER FOR EVALUATION OF INDETERMINATE THYROID NODULES AND CORRELATION WITH ULTRASOUND RISK ASSESSMENT: SINGLE INSTITUTIONAL EXPERIENCE. ATA, FNA, NIFTP, TI-RADS
17  2019 Afirma Gene Sequencing Classifier Compared with Gene Expression Classifier in Indeterminate Thyroid Nodules. Cyto-I, GSC, NPV, PPV
18  2019 Chronic Lymphocytic Thyroiditis May Lower Accuracy of AUS/FLUS Cytopathology in Surgical Patients. AUS, CLT, FLUS, PPV
19  2019 Comparison of Postmarketing Findings vs the Initial Clinical Validation Findings of a Thyroid Nodule Gene Expression Classifier: A Systematic Review and Meta-analysis. BCR, DOR, PPV
20  2019 Correction to: Evaluation of 167 Gene Expression Classifier (GEC) and ThyroSeq v2 Diagnostic Accuracy in the Preoperative Assessment of Indeterminate Thyroid Nodules: Bivariate/HROC Meta-analysis. ---
21  2019 Hurthle cell predominance impacts results of Afirma gene expression classifier and ThyroSeq molecular panel performance in indeterminate thyroid nodules. ROM
22  2019 Identification of Hurthle cell cancers: solving a clinical challenge with genomic sequencing and a trio of machine learning algorithms. FNAB, GSC, LOH, ML, SVM
23  2019 Independent Comparison of the Afirma Genomic Sequencing Classifier and Gene Expression Classifier for Cytologically Indeterminate Thyroid Nodules. BCR, GSC
24  2019 Negative Results on Thyroid Molecular Testing Decrease Rates of Surgery for Indeterminate Thyroid Nodules. ---
25  2019 Performance of the Afirma genomic sequencing classifier versus gene expression classifier: An institutional experience. FNA, GSC
26  2019 Real-world Comparison of Afirma GEC and GSC for the Assessment of Cytologically Indeterminate Thyroid Nodules. BCRs, GSC, NPV, PPV
27  2019 The Diagnostic Performance of Afirma Gene Expression Classifier for the Indeterminate Thyroid Nodules: A Meta-Analysis. DOR, FNA, ITNs, NPV, PPV, SROC
28  2018 Evaluation of 167 Gene Expression Classifier (GEC) and ThyroSeq v2 Diagnostic Accuracy in the Preoperative Assessment of Indeterminate Thyroid Nodules: Bivariate/HROC Meta-analysis. NPV, PPV
29  2018 Gene Expression Classifier vs Targeted Next-Generation Sequencing in the Management of Indeterminate Thyroid Nodules. ---
30  2018 Molecular testing for indeterminate thyroid nodules: Performance of the Afirma gene expression classifier and ThyroSeq panel. NIFTP, PPV
31  2018 Preoperative Molecular Markers in Thyroid Nodules. NPV, PPV, Se, Sp
32  2018 Shear wave elastography and Afirma™ gene expression classifier in thyroid nodules with indeterminate cytology: a comparison study. BC, FNAB, NPV, PPV, ROC, SWE, SWV, TNs
33  2018 STATISTICAL COMPARISON OF AFIRMA GSC AND AFIRMA GEC OUTCOMES IN A COMMUNITY ENDOCRINE SURGICAL PRACTICE: EARLY FINDINGS. FNAB, GSC
34  2017 A Systematic Review of the Methods of Diagnostic Accuracy Studies of the Afirma Gene Expression Classifier. ---
35  2017 Comparative analysis of diagnostic performance, feasibility and cost of different test-methods for thyroid nodules with indeterminate cytology. BRAF, DOR, FNA, GAL-3-ICC, M/F, NGS
36  2017 Determining Patient Preferences for Indeterminate Thyroid Nodules: Observation, Surgery or Molecular Tests. GMP
37  2017 European Thyroid Association Guidelines regarding Thyroid Nodule Molecular Fine-Needle Aspiration Cytology Diagnostics. FNA
38  2017 How "suspicious" is that nodule? Review of "suspicious" Afirma gene expression classifier in high risk thyroid nodules. FA, ND, NG, SN
39  2017 Identification of parathyroid tissue in thyroid fine-needle aspiration: A combined approach using cytology, immunohistochemical, and molecular methods. FNAs, IHC, PT
40  2017 Molecular Profiling of Thyroid Nodules: Current Role for the Afirma Gene Expression Classifier on Clinical Decision Making. NPV
41  2017 Pre-operative features of non-invasive follicular thyroid neoplasms with papillary-like nuclear features: An analysis of their cytological, Gene Expression Classifier and sonographic findings. NIFTP
42  2017 Qualifiers of atypia in the cytologic diagnosis of thyroid nodules are associated with different Afirma gene expression classifier results and clinical outcomes. AUS, AUS-A, FNA
43  2017 The impact of noninvasive follicular thyroid neoplasm with papillary-like nuclear features on the performance of the Afirma gene expression classifier. AUS, NIFTP, SFN
44  2016 Association of Malignancy Prevalence With Test Properties and Performance of the Gene Expression Classifier in Indeterminate Thyroid Nodules. NPV
45  2016 Clinical Factors Influencing the Performance of Gene Expression Classifier Testing in Indeterminate Thyroid Nodules. HCNs
46  2016 Correlating thyroid cytology and histopathology: Implications for molecular testing. FNAs, NPV
47  2016 Gene expression classifier for the diagnosis of indeterminate thyroid nodules: a meta-analysis. ---
48  2016 Impact of Afirma gene expression classifier on cytopathology diagnosis and rate of thyroidectomy. FNAs
49  2016 Impact of the Afirma Gene Expression Classifier Result on the Surgical Management of Thyroid Nodules with Category III/IV Cytology and Its Correlation with Surgical Outcome. FNA, PPV, SFN
50  2016 Intrathyroidal Clear Cell Tumor of Parathyroid Origin with Review of Literature. TFT, WCCA
51  2016 LONG-TERM NONOPERATIVE RATE OF THYROID NODULES WITH BENIGN RESULTS ON THE AFIRMA GENE EXPRESSION CLASSIFIER. ---
52  2016 Noninvasive Follicular Variant of Papillary Thyroid Carcinoma and the Afirma Gene-Expression Classifier. AUS/FLUS, FNA, NFVPTC, SFN
53  2016 The diagnostic application of RNA sequencing in patients with thyroid cancer: an analysis of 851 variants and 133 fusions in 524 genes. FNA, PTC
54  2016 Usage trends and performance characteristics of a "gene expression classifier" in the management of thyroid nodules: An institutional experience. FNA
55  2016 Utility and cost-effectiveness of molecular testing in thyroid nodules with indeterminate cytology. MMT, StC
56  2016 UTILITY OF ULTRASOUND VERSUS GENE EXPRESSION CLASSIFIER IN THYROID NODULES WITH ATYPIA OF UNDETERMINED SIGNIFICANCE. AUS, FNA, PPV, USG
57  2016 Young Investigator Challenge: Molecular testing in noninvasive follicular thyroid neoplasm with papillary-like nuclear features. AUS, FLUS, FVPTC, NIFTP, UPMC
58  2015 Afirma Benign Thyroid Nodules Show Similar Growth to Cytologically Benign Nodules During Follow-Up. Cyto-B
59  2015 Afirma GEC and thyroid lesions: An institutional experience. FNA
60  2015 Effect of Gene Expression Classifier Molecular Testing on the Surgical Decision-Making Process for Patients With Thyroid Nodules. ---
61  2015 Effect of malignancy rates on cost-effectiveness of routine gene expression classifier testing for indeterminate thyroid nodules. QALY
62  2015 Has Afirma gene expression classifier testing refined the indeterminate thyroid category in cytology? FNA
63  2015 Wide Inter-institutional Variation in Performance of a Molecular Classifier for Indeterminate Thyroid Nodules. ITNs, MSBI, MSK, NPVs, PPVs
64  2014 A practical method to determine the site of unknown primary in metastatic neuroendocrine tumors. IHC, NET, PNET
65  2014 An independent study of a gene expression classifier (Afirma) in the evaluation of cytologically indeterminate thyroid nodules. ---
66  2014 Clinical diagnostic gene expression thyroid testing. ---
67  2014 Cost-effectiveness of molecular testing for thyroid nodules with atypia of undetermined significance cytology. AUS, GMP
68  2013 Does addition of BRAF V600E mutation testing modify sensitivity or specificity of the Afirma Gene Expression Classifier in cytologically indeterminate thyroid nodules? CI
69  2013 Multicenter clinical experience with the Afirma gene expression classifier. AUS/FLUS, FN
70  2013 Surgical utility of Afirma: effects of high cancer prevalence and oncocytic cell types in patients with indeterminate thyroid cytology. FNA, NPV, TCP
71  2013 Use of the afirma gene expression classifier for preoperative identification of benign thyroid nodules with indeterminate fine needle aspiration cytopathology. FNA
72  2012 Analytical performance verification of a molecular diagnostic for cytology-indeterminate thyroid nodules. FNAs